Cotteel M, Dequiedt P, Potier A, Puech F, Lelièvre G, Leroy J L, Tacquet A, Delecour M
J Gynecol Obstet Biol Reprod (Paris). 1979 Apr-May;8(3):253-9.
The authors studied 43 cases of arterial hypertension in pregnancy in an attempt to determine the efficiency and safety of different anti-hypertensive drugs. The patients were divided into two major groups: arterial hypertension which revealed itself during pregnancy (true toxaemias of pregnancy and relapsing toxaemias), and arterial hypertensions which were added on to a pre-existing pathology (arterial hypertension, diabetes, chronic nephritis). The cases in these different classes were then divided into two definite groups according to the need for therapy: the first group was treated by rest and hydrallazine as a single therapeutic agent. In the second group multiple agents were needed because of the arterial hypertension, and one was a beta-blocker. Complications were found particularly in the second group of true toxaemias of pregnancy where unfortunately 5 fetal deaths occurred that were attributable to the severity of the hypertension more than to the beta-blockers, which were administered for longer and in higher doses without major complications in recurrent toxaemias and pre-existing arterial hypertension cases.
作者研究了43例妊娠期动脉高血压病例，试图确定不同抗高血压药物的有效性和安全性。患者被分为两大组：妊娠期出现的动脉高血压（真性妊娠中毒症和复发性妊娠中毒症），以及叠加于原有疾病（动脉高血压、糖尿病、慢性肾炎）之上的动脉高血压。然后根据治疗需要将这些不同类型的病例分为两个明确的组：第一组通过休息和使用肼屈嗪作为单一治疗药物进行治疗。在第二组中，由于动脉高血压需要使用多种药物，其中一种是β受体阻滞剂。并发症尤其在第二组真性妊娠中毒症中被发现，不幸的是，该组有5例胎儿死亡，这更多归因于高血压的严重程度，而非β受体阻滞剂，在复发性妊娠中毒症和原有动脉高血压病例中，β受体阻滞剂使用时间更长、剂量更高，但未出现重大并发症。
